Roche’s Tecentriq Gets Another Indication In India But Pricing Hurts
Executive Summary
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.
You may also be interested in...
IQVIA Exec On Putting India Firmly In IO Trials Reckoning
An IQVIA executive in Asia sees scope for India to figure routinely on the radar of sponsors for immuno-oncology trials and outlines how some gaps to get there can be plugged.
India's SPARC Keeps Paclitaxel Ambition Burning For Now
A US Complete Response Letter for SPARC’s paclitaxel product has cast a cloud over the project’s viability, but the company is still hopeful of an FDA approval by the fourth quarter of fiscal 2021. With the delay in commercialization, investment in some prioritized projects might also require external funding or even an exit from other research assets.
Will Keytruda Price Differential Really Count In India?
Merck has launched Keytruda at an “India-specific” price but some experts say that the immuno-oncology therapy will likely still be beyond the reach of a majority of patients. Merck though also expects to offer a patient access program for those who can’t afford the therapy.